ATTACHMENT E: JOURNAL INFORMATION PIECE FOR INFECTIOUS DISEASE SPECIALISTS
ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administration (FDA) for three indications:

- Adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs) with a recommended ACTEMRA dosing interval of every 4 weeks for intravenous (IV) or every other week or weekly for subcutaneous (SC) administration.

- Children 2 years of age and older with active Polyarticular Juvenile Idiopathic Arthritis (PJIA) with a recommended ACTEMRA dosing interval of every 4 weeks for IV administration.

- Children 2 years of age and older with active Systemic Juvenile Idiopathic Arthritis (SJIA) with a recommended ACTEMRA dosing interval of every 2 weeks for IV administration.

The safety and efficacy of ACTEMRA® for conditions other than RA, PJIA and SJIA have not yet been established.

**Infectious disease specialists** should be aware of important safety information regarding ACTEMRA.

**Serious infections:** Patients treated with ACTEMRA are at increased risk for developing serious infections leading to hospitalization or death including tuberculosis (TB), bacterial, invasive fungal, viral and other opportunistic infections.

Avoid ACTEMRA during an active infection, including localized infections. If a serious infection develops, hold ACTEMRA until the infection is controlled.

**Reporting Adverse Events**
It is important that you report all serious infections that occur in patients being treated with ACTEMRA, even if you do not think there is a causal relationship. The information that you, as an infectious disease specialist, provide about these events may inform therapy and monitoring decisions for future patients.

**Reporting maintains patient confidentiality.** Your patient’s name or contact information is not needed. *HIPAA does not apply to this adverse event reporting.*
You can report your cases to Genentech or directly to the FDA:

- Genentech at 1-888-835-2555
- MedWatch (FDA safety information and adverse event reporting program) at 1-800-332-1088 or online at [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm)

Please visit [www.ACTEMRA.com](http://www.ACTEMRA.com) for Prescribing Information and Medication Guide.